循环微RNA-196a是早期胃癌的生物标志物。
Circulating microRNA-196a is an early gastric cancer biomarker.
作者信息
Chen Tsung-Hsing, Lee Chieh, Chiu Cheng-Tang, Chu Yin-Yi, Cheng Hao-Tsai, Hsu Jun-Te, Tsou Yung-Kuan, Wu Ren-Chin, Chen Tse-Ching, Chang Nien-Chen, Yeh Ta-Sen, Lin Kwang-Huei
机构信息
Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan.
出版信息
Oncotarget. 2017 Dec 7;9(12):10317-10323. doi: 10.18632/oncotarget.23126. eCollection 2018 Feb 13.
MicroRNA-196a (miRNA-196a) is associated with the development of gastric cancer and metastasis. Intestinal metaplasia and low- or high-grade dysplasia are considered to be precursors of intestinal type gastric cancer. Accordingly, we investigated the expression of plasma miRNA-196a as an early detection biomarker in precancerous gastric lesions and early cancer (pT1a/b), which is otherwise treated with endoscopic submucosal dissection. Our data showed that levels of circulating (plasma) miRNA-196a were higher in patients with precancerous lesions/early gastric adenocarcinoma than in healthy controls. The area under the receiver operating characteristic curve (AUC) for healthy controls vs. intestinal metaplasia was 0.9736; healthy controls vs. low-grade/high-grade dysplasia 0.9495; and healthy controls vs. early gastric cancer 0.9318. These results indicate that circulating miRNA-196a is a novel biomarker for detection of early gastric cancer and its precursor.
微小RNA-196a（miRNA-196a）与胃癌的发生及转移相关。肠化生以及低级别或高级别发育异常被认为是肠型胃癌的癌前病变。因此，我们研究了血浆miRNA-196a作为癌前胃部病变及早期癌症（pT1a/b）早期检测生物标志物的表达情况，这些病变及早期癌症通常采用内镜下黏膜下剥离术进行治疗。我们的数据显示，癌前病变/早期胃腺癌患者循环（血浆）miRNA-196a水平高于健康对照者。健康对照者与肠化生患者相比，受试者工作特征曲线下面积（AUC）为0.9736；健康对照者与低级别/高级别发育异常患者相比，AUC为0.9495；健康对照者与早期胃癌患者相比，AUC为0.9318。这些结果表明，循环miRNA-196a是早期胃癌及其癌前病变检测的一种新型生物标志物。
Zotero 插件